An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome?

2015 ◽  
Vol 63 (2) ◽  
pp. 196-201 ◽  
Author(s):  
Natasha M. Archer ◽  
Renata Parada Amorim ◽  
Rafaela Naves ◽  
Simone Hettmer ◽  
Lisa R. Diller ◽  
...  
Keyword(s):  
Population Based ◽  
Cancer Predisposition ◽  
Malignant Neoplasms ◽  
Cancer Predisposition Syndrome ◽  
Increased Risk ◽  
Second Malignant Neoplasms

Second malignant neoplasms (SMN) among 18,627 testicular cancer survivors (TCS) after chemotherapy (CHEM) or surgery (SURG).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1536-1536
Author(s):  
Chunkit Fung ◽  
Sophie D. Fossa ◽  
Michael T Milano ◽  
Mandi Yu ◽  
Melissa Worman ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Population Based ◽  
Baseline Risk ◽  
Malignant Neoplasms ◽  
Solid Cancer ◽  
Site Specific ◽  
Increased Risk ◽  
Absolute Excess Risk ◽  
Second Malignant Neoplasms ◽  
Testicular Cancer Survivors

1536 Background: Increased risks of SMN after radiotherapy (RT) for testicular cancer (TC) are well established. Few population-based studies, however, have focused on SMN risk among a contemporary group of TCS managed initially with non-RT approaches, including CHEM. Methods: Standardized incidence ratios (SIR) of SMN stratified by site and time since TC diagnosis were calculated for 18,627 TCS reported to the SEER program (1980-2008) who initially had CHEM (n=8,058) or SURG (n=10,569) alone without RT, with each cohort accruing 65,398 and 92,681 person-years (PY) of follow-up respectively. Results: After CHEM, significantly increased risks of solid cancers (n=154; SIR 1.3; 95% CI 1.1-1.5; absolute excess risk (AER) 5.4 per 10,000 PY) and leukemias (n=18, SIR 3.9; 95% CI 2.3-6.1; AER 2.0) were observed. Solid cancer risk remained elevated for > 20 yrs, whereas excess leukemias were concentrated within 10 years after diagnosis. SIRs for solid cancers during the <1, 1-4, 5-9, 10-14, 15-19, and 20+ yr periods were 2.0 (95% CI 1.03-3.5), 1.4 (95% CI 0.97-2.0), 0.8 (95% CI 0.5-1.2), 1.3 (95% CI 0.9-1.8), 1.6 (95% CI 1.05-2.2), and 1.5 (95% CI 0.95-2.2) respectively (P-trend 0.5) whereas SIRs for leukemia were 3.2, 9.9 (P<0.05), 2.6, and 2.3 respectively, with no cases reported in the latter 2 intervals. Median latencies to the development of solid cancers and leukemia were 12.5 yr (0.1-28) and 2.5 yr (0.1-14) respectively. Increased site-specific risks were apparent for cancers of liver (SIR 1.9; 95% CI 0.6-4.4); pancreas (SIR 2.1; 95% CI 0.8-4.6); soft tissue (SIR 4.9; 95% CI 2.1-9.7); bladder (SIR 1.9; 95% CI 1.02-3.3); kidney (SIR 2.6; 95% CI 1.4-4.3); brain/CNS (SIR 1.8; 95% CI 0.7-3.7), and thyroid (SIR 3.9; 95% CI 2.1-6.6). Secondary leukemias included 16 non-lymphocytic and 2 lymphocytic leukemias. In contrast, among TCS managed initially with SURG alone, no excess solid cancers were observed (n=198; SIR 1.0; 95% CI 0.8-1.1), albeit an increased risk of leukemia (n=15; SIR 1.9; 95% CI 1.1-3.2, AER 0.8) was seen. Conclusions: Future analytic studies should further evaluate the site-specific risks of SMN after modern CHEM for TC and the baseline risk among patients managed with non-cytotoxic approaches.

scholarly journals Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain

2004 ◽  
Vol 91 (11) ◽  
pp. 1905-1910 ◽  
Author(s):  
H C Jenkinson ◽  
M M Hawkins ◽  
C A Stiller ◽  
D L Winter ◽  
H B Marsden ◽  
...  
Keyword(s):  
Childhood Cancer ◽  
Population Based ◽  
Malignant Neoplasms ◽  
Second Malignant Neoplasms

Utility of a Cancer Predisposition Screening Tool for Predicting Subsequent Malignant Neoplasms in Childhood Cancer Survivors

2021 ◽  
pp. JCO.21.00018
Author(s):  
Noelle Cullinan ◽  
Ian Schiller ◽  
Giancarlo Di Giuseppe ◽  
Mohammed Mamun ◽  
Lara Reichman ◽  
...  
Keyword(s):  
Cancer Survivors ◽  
Childhood Cancer ◽  
Conditional Logistic Regression ◽  
Childhood Cancer Survivors ◽  
Cancer Predisposition ◽  
Malignant Neoplasms ◽  
Primary Cancer ◽  
Primary Malignancy ◽  
Control Approach ◽  
Cancer Predisposition Syndrome

PURPOSE Childhood cancer survivors (CCS) are at risk of developing subsequent malignant neoplasms (SMNs) resulting from exposure to prior therapies. CCS with underlying cancer predisposition syndromes are at additional genetic risk of SMN development. The McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) tool identifies children with cancer at increased likelihood of having a cancer predisposition syndrome, guiding clinicians through a series of Yes or No questions that generate a recommendation for or against genetic evaluation. We evaluated MIPOGG's ability to predict SMN development in CCS. METHODS Using the provincial cancer registry (Ontario, Canada), and adopting a nested case-control approach, we identified CCS diagnosed and/or treated for a primary malignancy before age 18 years (1986-2015). CCS who developed an SMN (cases) were matched, by primary cancer and year of diagnosis, with CCS who did not develop an SMN (controls) over the same period (1:5 ratio). Potential predictors for SMN development (chemotherapy, radiation, and MIPOGG output) were applied retrospectively using clinical data pertaining to the first malignancy. Conditional logistic regression models estimated hazard ratios and 95% CIs associated with each covariate, alone and in combination, for SMN development. RESULTS Of 13,367 children with a primary cancer, 317 (2.4%) developed an SMN and were matched to 1,569 controls. A MIPOGG output recommending evaluation was significantly associated with SMN development (hazard ratio 1.53; 95% CI, 1.06 to 2.19) in a multivariable model that included primary cancer therapy exposures. MIPOGG was predictive of SMN development, showing value in nonhematologic malignancies and in CCS not exposed to radiation. CONCLUSION MIPOGG has additional value for SMN prediction beyond treatment exposures and may be beneficial in decision making for enhanced individualized SMN surveillance strategies for CCS.

scholarly journals Increased risk of second malignant neoplasms in adolescents and young adults with cancer

Cancer ◽  
2015 ◽  
Vol 122 (1) ◽  
pp. 116-123 ◽  
Author(s):  
Jean S. Lee ◽  
Steven G. DuBois ◽  
Peter F. Coccia ◽  
Archie Bleyer ◽  
Rebecca L. Olin ◽  
...  
Keyword(s):  
Young Adults ◽  
Adolescents And Young Adults ◽  
Malignant Neoplasms ◽  
Increased Risk ◽  
Second Malignant Neoplasms

scholarly journals Second malignant neoplasms after childhood cancer: A nationwide population-based study in Korea

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0207243 ◽  
Author(s):  
Hee Young Ju ◽  
Eun-Kyeong Moon ◽  
Jiwon Lim ◽  
Byung Kiu Park ◽  
Hee Young Shin ◽  
...  
Keyword(s):  
Childhood Cancer ◽  
Population Based ◽  
Malignant Neoplasms ◽  
Population Based Study ◽  
Second Malignant Neoplasms

Second Malignant Neoplasms in Patients Treated for Childhood Leukemia: A Population-based Cohort Study from the Nordic Countries

1991 ◽  
Vol 80 (12) ◽  
pp. 1220-1228 ◽  
Author(s):  
R. NYGAARD ◽  
S. GARWICZ ◽  
T. HALDORSEN ◽  
H. HERTZ ◽  
G. K. JONMUNDSSON ◽  
...  
Keyword(s):  
Cohort Study ◽  
Childhood Leukemia ◽  
Population Based ◽  
Nordic Countries ◽  
Malignant Neoplasms ◽  
Second Malignant Neoplasms
Sign in / Sign up

Export Citation Format

Share Document